Clinical trials: Soft-tissue Sarcoma, open to volunteers
Osteosarcoma, Sarcoma
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT05830123
- Testing
- HS-20093
- Where
- 11 sites in China
- Volunteers
- 170 people
- Sponsor
- Hansoh BioMedical R&D Company
Rhabdomyosarcoma
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Background: Rhabdomyosarcoma (RMS) is a cancer of soft tissues. It is the most common soft tissue sarcoma seen in children. RMS cancer cells have a protein called FGFR4 on their surface.
- Trial name
- NCT06865664
- Testing
- fludarabine, cyclophosphamide, cetuximab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Dilated Cardiomyopathy, Kaposi's Sarcoma-Associated Herpesvirus Infection
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
Evaluating the efficacy of sirolimus (compared to standard therapy alone) in the treatment of dilated cardiomyopathy infected with Kaposi Sarcoma-associated virus -- a multicenter randomized controlled study.
- Trial name
- SDCMK (NCT06236022)
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Tongji Hospital
Soft Tissue Sarcoma
Outcomes Following Limb Sparing Surgery for Soft Tissue Sarcoma
The goal of this study is to assess body image, health-related quality of life (QoL), and functioning (gait function, joint function, and walking ability) in patients after resection of localized soft tissue sarcoma (STS) of the…
- Trial name
- NCT06962072
- Testing
- Surgical resection with or without radiotherapy and/or chemotherapy
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Amsterdam UMC
Kaposi Sarcoma
A Study of Propranolol to Treat Kaposi Sarcoma
A clinical study of propranolol for the treatment of Kaposi Sarcoma in children and adults. This study will be an open-label single armed treatment trial that will test the effectiveness and the safety of treating Kaposi Sarcoma…
- Trial name
- NCT05797662
- Testing
- Propranolol
- Where
- 6 sites in Argentina, Brazil and 3 more
- Volunteers
- 25 people
- Sponsor
- AIDS Malignancy Consortium
Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST)
SPEARHEAD-3 Pediatric Study
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
- Conditions
- Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma
- Trial name
- NCT05642455
- Testing
- Afamitresgene autoleucel
- Where
- 10 sites in United States
- Volunteers
- 20 people
- Sponsor
- USWM CT, LLC
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04534127
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 56 people
- Sponsor
- Alpha Tau Medical LTD.
Sarcoma
Registration Study Sarcoma
The prospective and retrospective data collection on bone and soft tissue sarcoma is an observational cohort study aimed to collect clinical data and patient reported outcomes of all patients who have been diagnosed with bone or…
- Trial name
- NCT05373810
- Testing
- Surgery
- Where
- 2 sites in Netherlands
- Volunteers
- 1,000 people
- Sponsor
- Radboud University Medical Center
Effectiveness, Sexuality
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
A total of 60 patients with metastatic/surgically unresectable bone and soft tissue sarcomas who had previously received multi-target TKI therapy and failed were enrolled to evaluate the efficacy and safety.
- Trial name
- NCT05617859
- Testing
- Lenvatinib mesylate capsule
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Myxoid Liposarcoma
International Prospective Registry on Local Treatment Approaches in MLS
To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS)
- Trial name
- NCT04699292
- Testing
- Surgery, Preoperative RT 36Gy, Preoperative RT 50Gy
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- The Netherlands Cancer Institute
Osteosarcoma, Transcriptome
Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study
Bagaev et al. have identified four tumor microenvironment (TME) subtypes that are conserved across diverse cancers and correlated with immunotherapy response in melanoma, bladder, and gastric cancers.
- Conditions
- Osteosarcoma, Transcriptome, Tumor Microenvironment, Precision Medicine
- Trial name
- PTMTO (NCT06776198)
- Testing
- Chemotherapy
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Glioma, Hematopoietic and Lymphoid Cell Neoplasm
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
This study performs standardized testing of tumor tissue samples to learn which genes are mutated (have changed) in order to provide personalized cancer therapy options to cancer patients at MD Anderson.
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Melanoma
- Trial name
- NCT01772771
- Testing
- Biospecimen Collection, Genetic Testing, Medical Chart Review
- Where
- United States
- Volunteers
- 12,000 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Soft-tissue Sarcoma
Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma
Soft tissue sarcoma (STS) is a kind of solid tumor with high heterogeneity. There is no standard second-line treatment plan for patients who have failed first-line treatment.
- Trial name
- NCT05620693
- Testing
- NY-ESO-1 TCR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen University General Hospital
Low Grade Endometrial Stromal Sarcoma
Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)
The primary objective is to compare the progression-free survival (PFS) between aromatase inhibitors interruption and aromatase inhibitors maintenance strategies in patients with a locally advanced or metastatic Low Grade…
- Trial name
- BFR-ESS (NCT03624244)
- Testing
- Aromatase Inhibitors
- Where
- 22 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Leon Berard
DLBCL - Diffuse Large B Cell Lymphoma
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Gemcitabine and Oxaliplatin vs Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory…
- Trial name
- NCT07570823
- Testing
- SCTB35 injection, Rituxumab, Gemcitabine
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Sinocelltech Ltd.
Rhabdomyosarcoma
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
This is a phase II study to determine safety and efficacy of combining liposomal irinotecan with vincristine alternating with VAC in intermediate-risk patients, liposomal irinotecan with temozolomide and vincristine alternating…
- Trial name
- NCT06023641
- Testing
- Vincristine, Dactinomycin, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- St. Jude Children's Research Hospital
Primary, Sarcoma
Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma
This randomized, non-inferiority clinical trial aims to evaluate whether non-resection of needle biopsy tract is non-inferior to routine biopsy tract resection in terms of local recurrence in patients with primary extremity…
- Trial name
- NCT07575724
- Testing
- biopsy tract resection, biopsy tract non-resection
- Where
- 2 sites in China
- Volunteers
- 3,300 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Maligant Solid Tumor, Head & Neck Cancer
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
This study is a prospective, single-arm, open-label, dose-escalation study. A total of 4 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles.
- Conditions
- Maligant Solid Tumor, Head & Neck Cancer, Thyroid Cancer, Lung Cancer - Non Small Cell Squamous
- Trial name
- NCT07459283
- Testing
- INN805
- Where
- China
- Volunteers
- 10 people
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
Osteosarcoma
Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma
Prospective, open, interventional, randomized, non-commercial trial
- Trial name
- Dragonfly (NCT07787429)
- Testing
- Mifamurtide, Sorafenib
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Anna Raciborska
Sarcoma
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez. We want to see if this medicine can help people with certain types of cancer, whether its safe to use, how well people tolerate it…
- Trial name
- NCT07602777
- Testing
- Ris-Rez, G-CSF
- Where
- 13 sites in United States, Canada and 4 more
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline